CNS Pharmaceuticals (CNSP) Proxy filing summary

Executive summary

• Annual meeting scheduled for September 30, 2026, at 12:00 PM EST, to be held virtually.

• Shareholders are encouraged to review materials and vote on key proposals affecting governance and compensation.

Voting matters and shareholder proposals

• Election of six directors for terms expiring at the 2027 annual meeting or until successors are elected.

• Ratification of MaloncBailey, LLP as independent registered public accounting firm for fiscal year ending December 31, 2026.

• Advisory, non-binding vote on executive compensation.

• Approval of amendments to the 2020 Stock Plan, including an increase of 650,000 authorized shares.

• Authorization to adjourn the meeting if additional proxy solicitation is needed.

Board of directors and corporate governance

• Board recommends voting in favor of all proposals, including director elections and amendments to the stock plan.

• Director nominees include Faith Charles, Bettina Cockroft, Michal Fisher, Jeffry R. Keyes, Rami Levin, and Amy Mahery.